Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as 5% Potassium nitrate
5% nitrate · 1 trial · 1 indication
Response to a one second application of air from a standard dental unit syringe applied to the surface of hypersensitive tooth. After each stimuli participant rated the intensity of pain on a 100 millimeter VAS, on which 0 represented "no pain" and 100 represented the" worst pain imaginable". Change from baseline was calculated as mean score at the given time point minus mean score at baseline.
| Arm | Type | Description |
|---|---|---|
| 5% KNO3 solution | EXPERIMENTAL | Participants to apply 5% potassium nitrate solution to a single sensitive tooth for two minutes, in each of the five day treatment period. |
| 2.5% KNO3 solution | EXPERIMENTAL | Participants to apply 2.5% potassium nitrate solution to a single sensitive tooth for two minutes, in each of the five day treatment period. |
| Sterile Water | PLACEBO_COMPARATOR | Participants to apply sterile water to a single sensitive tooth for two minutes, in each of the five day treatment period. |
| Name | Type | Description |
|---|---|---|
| 5% Potassium nitrate | DRUG | 5% potassium nitrate solution |
| 2.5% Potassium nitrate | DRUG | 2.5% potassium nitrate solution |
| Sterile water | OTHER | Sterile water |
Inclusion Criteria: * Self-reported history of dentinal hypersensitivity lasting more than 6 months and a primary complaint of sensitive teeth * Three teeth that can be isolated that meet all of the following criteria at the screening visit: * Teeth showing signs of facial/cervical gingival recessi...
5% nitrate is being developed for dentine hypersensitivity, a condition in which exposed dentine causes tooth pain in response to stimuli. It is a small molecule formulation studied in a Phase 2 trial evaluating whether it reduces dentinal hypersensitivity. It is not approved and remains investigational.
Yes, 5% nitrate is also known as 5% potassium nitrate. The two names refer to the same small molecule asset developed by GSK plc for dentine hypersensitivity. Readers searching either name will find the same Phase 2 program and the same clinical trial record.
5% nitrate is developed by GSK plc, which trades under the ticker GSK. GSK is the sponsor of the clinical program evaluating the asset in dentine hypersensitivity. No other developer or partner is associated with this asset in the available program information.
5% nitrate is in Phase 2 development. The program has one completed Phase 2 trial in dentine hypersensitivity, with no active trials currently listed. It is an investigational small molecule and has not been approved for any indication.
5% nitrate has been studied in one completed Phase 2 trial, NCT01115452, titled Efficacy of Potassium Nitrate Solution in Reducing Dentinal Hypersensitivity. The trial enrolled 32 participants in the United States, was randomized, double blind, and placebo controlled, and included adults aged 18 years and older.